In this webinar, BioSpace will gathered experts to discuss China’s impact on the future of biotech and how both U.S. and Chinese companies can thrive—and maybe even collaborate.

Original title: “Webinar: The China question: Can US biotechs lead as investment heads east?”

A new biotech co-founded by Paul Stoffels has formed to take on the CAR T cell assets of Galapagos almost a year after the company—now known as Lakefront Biotherapeutics—abandoned them.

Original title: “Stoffels strikes up new biotech in return to Galapagos cell therapy mission”

Prosecutors say the company filled unnecessary prescriptions that fueled the opioid epidemic. A spokesperson for CVS said the company admitted to no wrongdoing and “strongly disagreed” with the case’s claims.

Original title: “CVS to pay $315M to settle opioid prescribing allegations”

Since his release from prison in 2022, Martin Shkreli has traded stocks and publicly opined on news events, damaging reputations and sinking share prices for small biotechs including Capricor and Cassava, the FTC alleges.

Original title: “‘Pharma bro’ Shkreli runs afoul of court’s lifetime pharma ban”

The layoffs across GSK’s Belgium sites come on the heels of the pharma’s planned shuttering of its German vaccine manufacturing site, which prompted job cuts for about 650 employees.

Original title: “GSK plans 1.2K+ layoffs at Belgium sites as $2.5B restructure gains momentum”

A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product expansion fell short.

Original title: “J&J earnings set ‘negative tone’; Shkreli vs. the FTC”